Here are five key things investors need to know to start the trading day:
1. Work in progress
Home Depot kicked off this week’s string of retailer earnings reports on a sour note. The home improvement retailer missed analyst expectations on both lines for the first time since 2014, but the company still maintained its full-year outlook. Attention on the earnings front will now turn to Lowe’s, Target and TJX, all three of which are set to report before the bell on Wednesday. Walmart is expected to release its quarterly results before the bell on Thursday. Follow live markets updates here.
2. Europe courts Trump
(L/R) Ukrainian President Volodymyr Zelenskyy, French President Emmanuel Macron and US President Donald Trump participate in a meeting with European leaders in the East Room of the White House in Washington, DC, on August 18, 2025.
Andrew Caballero-Reynolds | AFP | Getty Images
Three days after President Donald Trump met with Russian President Vladimir Putin in Alaska, it was Ukrainian President Volodymyr Zelenskyy and European leaders’ turn to meet with the U.S. president. The group visited the White House on Monday and discussed the potential for security guarantees for Ukraine amid its war with Russia. Zelenskyy also reportedly said that Ukraine offered to buy $90 billion in U.S. weapons. Trump said he called Putin following the summit and “began the arrangements for a meeting” between the Russian and Ukrainian presidents. Catch up on the biggest moments from Monday’s meeting by reading CNBC’s coverage.
3. Dose of GLP-1 news
Containers of Ozempic and Wegovy seen at Children’s Hospital in Aurora, CO, Nov. 18, 2024.
Kevin Mohatt | The Washington Post | Getty Images
Novo Nordisk provided two major updates on its blockbuster weight-loss drugs in recent days. First, Novo Nordisk said cash-paying U.S. patients could buy Ozempic for less than half of its monthly sticker price. As CNBC’s Annika Kim Constantino reports, the move comes as drugmakers are under pressure from the Trump administration to lower costs. The news comes after the company announced on Friday that Wegovy, another obesity drug, earned accelerated approval from U.S. regulators to treat a serious liver disease. The approval makes Wegovy the first in the GLP-1 drug class to be cleared for such use. Investors appeared to like the two updates: U.S.-listed shares of Novo rallied more than 3% on Monday and another 1.3% in Tuesday’s premarket.
4. The AI race
OpenAI CEO Sam Altman speaks during the Federal Reserve’s Integrated Review of the Capital Framework for Large Banks Conference in Washington, D.C., U.S., July 22, 2025.
Ken Cedeno | Reuters
As the battle to develop the best artificial intelligence technology heats up between China and the U.S., one of the industry’s top executives has a warning. Sam Altman, CEO of OpenAI, said during a rare event with reporters that he was “worried about” China. “There’s inference capacity, where China probably can build faster. There’s research, there’s product; a lot of layers to the whole thing,” he said. “I don’t think it’ll be as simple as: Is the U.S. or China ahead?” Altman’s comments come as the U.S. seeks to control AI-related exports to the Asian country, though Altman said such measures may not hinder development as much as some hope. In other tech news, Intel and SoftBank announced Monday that the chipmaker would get a $2 billion investment from the Japanese company.
5. ‘Job hugging’
gorodenkoff | iStock | Getty Images Plus
You’ve likely heard of “quiet quitting” or the “great resignation.” Now, the latest workplace trend is “job hugging,” CNBC’s Greg Iacurci reports. In short, the term describes how workers are holding on tightly to their current roles despite any displeasure, as a result of what they perceive as a weak labor market. For evidence, look no further than the U.S. Labor Department’s Job Openings and Labor Turnover Survey: Excluding the early days of the Covid-19 pandemic, the rate of workers voluntarily leaving their jobs is sitting around levels that haven’t been seen since 2016.
— CNBC’s Melissa Repko, Annika Kim Constantino, Karen Gilchrist, MacKenzie Sigalos and Greg Iacurci contributed to this report.